Skip to content

Scholar Rock SRRK Stock-Based Comp

Stock-Based Comp at other companies

Biogen logo
BiogenBIIB
$84M+3.7%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
$8.72M-3.8%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$23.42M+29.7%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$13.08M+0.5%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$6.26M+7.0%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$16.91M+68.9%

Segments

By segment

See full
Single Reportable$18.25M+36.0%

Other financials

Income statement

See full
Revenue-
Operating income-$102.0M-32.3%
Net income-$105.5M-41.2%
EPS (diluted)-$0.83-23.9%

Balance sheet

See full
Cash & equivalents$430.5M+212%
Total debt$205.7M+226%
Total equity$276.0M-11.6%
Total assets$535.3M+31.3%

Cash flow

See full
Operating cash flow-$82.1M-4.4%
CapEx$68.0K-74.9%
Free cash flow-$82.2M-4.1%

Valuation

See full
Market cap$5.67B+85.5%

Profitability

See full
Operating margin-231.8%
Net margin-236.9%
FCF margin-309.1%

Returns & leverage

See full
Return on equity-138.9%+60.1pp
Debt / equity0.7×+0.5×
Current ratio8.6×-1.6×

Where this comes from

Reported directly by Scholar Rock in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scholar Rock's stock-based comp?
Scholar Rock (SRRK) reported stock-based comp of $18.25M in Q1 2026.
How has Scholar Rock's stock-based comp changed year-over-year?
Scholar Rock's stock-based comp increased by 36.0% year-over-year, from $13.41M to $18.25M.
What is the long-term trend for Scholar Rock's stock-based comp?
Over 4 years (2021 to 2025), Scholar Rock's stock-based comp has grown at a 34.4% compound annual growth rate (CAGR), from $23.15M to $75.6M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.